clinical trial · NCT07294534
A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX87in Combination With HLX22 or Pertuzumab in the Neoadjuvant Therapy of HER2-Positive Bresat Cancer
Shanghai Henlius Biotech·phase3·not yet recruiting·n = 817
HER2 + Breast CancerHLX87+HX22HLX87 + PertuzumabTCbHP
brief summary
The study is being conducted to evaluate the clinical efficacy of HLX87 in combination with HLX22 or pertuzumab vs. TCbHP in the neoadjuvant therapy of HER2-positive early or locally advanced breast cancer.
started
Jan 27, 2026
primary completion
Sep 30, 2028
completion
Feb 1, 2030
last updated
Dec 19, 2025
official title
An Open-Label, Randomized, Multicenter Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX87 (HER2 ADC) in Combination With HLX22 (Recombinant Humanized Anti-HER2 Monoclonal Antibody Injection) or Pertuzumab vs. TCbHP in the Neoadjuvant Therapy of HER2-Positive Early or Locally Advanced Breast Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol